Rubicon Research
Rubicon Research is an Indian publicly listed pharmaceutical formulations company developing specialty generic and drug-device combination products (oral solids, liquids, nasal sprays) for regulated markets, primarily the US, leveraging proprietary drug delivery platforms like RubiReten® and RubiSRL® and US FDA-accredited manufacturing facilities.
- Company typePublic
- Founded1999
- HeadquartersMumbai, India
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Rubicon Research does
Rubicon Research Limited is a publicly listed Indian pharmaceutical formulations company, founded in 1999 and headquartered in Thane, Maharashtra, that develops, manufactures, and commercializes specialty generic and drug-device combination products for regulated markets. The company's portfolio spans 69 active ANDA and NDA products (55 commercialized in the US as of March 2024), including oral solids, oral liquids, ophthalmic drops, intrathecal injections, and nasal sprays, supported by 9-10 proprietary drug delivery technology platforms (notably the RubiReten® gastro-retentive system and the RubiSRL® sustained-release liquid platform) and 19 granted patents across India and the US. Manufacturing is conducted from two US FDA, MHRA UK, Health Canada, TGA Australia, and WHO-GMP accredited facilities in Ambernath and Satara (Maharashtra), with R&D centers in Thane and Concord, Ontario (Canada).
The business model is a B2B enterprise sales motion targeting the US regulated pharmaceutical market, with approximately 98% of revenue denominated in US dollars. Products are commercialized in the US through wholly-owned subsidiaries AdvaGen Pharma Ltd (established 2022 as the proprietary sales/marketing front-end) and Validus Pharmaceuticals LLC (acquired February 2024, specializing in two CNS therapy brands with no substitutable FDA-approved generics), supplemented by third-party distributors. Revenue streams include pharmaceutical product sales (one-time licensing through commercial supply arrangements) and selective contract manufacturing services for India, Australia, and New Zealand. Following the April 2026 acquisition of an 85% stake in Arinna Lifesciences (Rs 175.92 crore), the company is expanding into India's domestic CNS formulations market, where Arinna brings 60+ brands and access to 4,000+ prescribers. The company is listed on BSE and NSE (NSE: RUBICON) following a Rs 1,377.5 crore IPO in October 2025, which was oversubscribed 103.90 times. FY26 reported revenue of Rs 1,753.95 crore (+36.57% YoY) and net profit of Rs 246.73 crore (+83.63% YoY), with a market capitalization of approximately Rs 18,602.58 crore as of June 2026.
Rubicon Research firmographics
Firmographics- Name
- Rubicon Research
- Legal name
- Rubicon Research Limited
- Website
- https://rubicon.co.in
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Rubicon Research is an Indian publicly listed pharmaceutical formulations company developing specialty generic and drug-device combination products (oral solids, liquids, nasal sprays) for regulated markets, primarily the US, leveraging proprietary drug delivery platforms like RubiReten® and RubiSRL® and US FDA-accredited manufacturing facilities.
- Ownership category
- akta.pro rank
Rubicon Research industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)
- akta.pro secondary industry
- Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)
Keywords
Where Rubicon Research is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices5 records
Markets served
Rubicon Research business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Revenue generated from manufacturing and commercializing generic and specialty pharmaceutical products, primarily in the US market. The company had 55 commercialized products in the US as of March 2024, with 69 active NDAs/ANDAs. Approximately 98% of revenue is denominated in US dollars.
- Contract Manufacturing Services: The company provides contract manufacturing services to select customers for India, Australia, and New Zealand markets, complementing its proprietary product business.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels3 records
Rubicon Research product offering
Product offeringCore offering
Rubicon Research is a pharmaceutical formulations company that develops, manufactures, and commercializes generic and specialty pharmaceutical products, including drug-device combinations, primarily targeting the United States and other regulated markets. The company operates four manufacturing facilities (three in India and one R&D facility in Canada) and maintains a portfolio of 69 active ANDA/NDA products with 55 commercialized products in the US market.
Product overview
Rubicon Research is a pharmaceutical formulations company with a portfolio of 69 active ANDA and NDA products (55 commercialized in the US as of March 2024). The company operates through its core generic and specialty pharmaceutical products, supported by proprietary drug delivery technology platforms (RubiReten® and RubiSRL®). Commercial operations are conducted via wholly-owned subsidiaries: AdvaGen Pharma (established 2022 for US sales/marketing) and Validus Pharmaceuticals (acquired 2024, specializing in CNS brands). The company expanded into the Indian domestic market in 2026 through the acquisition of Arinna Lifesciences. Additional subsidiaries include Rubicon Consumer Healthcare (consumer OTC products) and KIA Health Tech (merger in progress).
Differentiator
Problem solved
Functional benefit
Brands
- Rubicon Consumer Healthcare: Consumer healthcare products division operating under rubiconconsumer.com
- AdvaGen Pharma
- Validus
Products and services
- Generic Pharmaceutical Products Portfolio Portfolio of generic pharmaceutical formulations including 55 commercialized products in the US market across multiple therapeutic categories. Products are developed, manufactured at Rubicon's Indian facilities, and commercialized through wholly-owned US subsidiaries AdvaGen Pharma and Validus Pharmaceuticals.
- Specialty Pharmaceutical Products Specialty pharmaceutical products including drug-device combinations and complex formulations leveraging proprietary RubiReten® and RubiSRL® drug delivery platforms. Distributed in the US through Validus Pharmaceuticals (acquired 2024) and AdvaGen Pharma.
- Technology Transfer Services Service offering providing technology transfer of proprietary drug delivery formulations, manufacturing processes, and regulatory expertise to pharmaceutical partners. Leverages the company's RubiReten®, RubiSRL®, and other drug delivery technology platforms.
Quantifiable outcome
- 69 active ANDA and NDA products approved by US FDA as of March 2024
- +3 more outcomes
Companies that use Rubicon Research
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
Rubicon Research technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Rubicon Research partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Arinna LifesciencescoreRubicon Research acquired 85% equity stake in Arinna Lifesciences for ₹175.92 crore, valuing the company at enterprise value of ₹200 crore on cash and debt-free basis. Arinna is a CNS-focused branded pharmaceutical marketing company with 60+ brands, 4,000+ prescribers, and established distribution network in India. Reported FY25 turnover of ₹71.5 crore. Transaction aligns with Rubicon's strategy to leverage its IP and chronic product portfolio for Indian domestic market.
- NeuronasalminorRubicon Research made a strategic investment of up to $2.5 million in US-based Neuronasal.
- Gen1e Lifesciences Inc.minorRubicon Research unit entered into a definitive agreement with Gen1e Lifesciences Inc. for strategic partnership.
- Validus Pharmaceuticals LLCcoreAcquired Validus Pharmaceuticals LLC in February 2024 to market two CNS therapy brands in the US specialty pharmaceutical market. These brands do not have substitutable generics approved by USFDA, strengthening Rubicon's specialty pharmaceutical business in the US.
- MUFG Intime India Private LimitedminorMUFG Intime India Private Limited (formerly Link Intime India Private Limited) serves as the Registrar and Share Transfer Agent for Rubicon Research, handling investor services and share transfer operations.
Scale indicators8 records
Recent moves8 records
Expansion highlights5 records
Rubicon Research competitors and assessment
Company assessmentBroad incumbents
- Aurobindo Pharma: One of India's largest generic pharmaceutical manufacturers with a substantial US ANDA portfolio and vertically integrated manufacturing. Comparable to Rubicon in targeting regulated US markets with generic formulations, though at much larger scale and broader therapeutic coverage.
- Lupin Limited: Indian-headquartered global generic pharma major with significant US presence and complex generics/specialty focus. Comparable to Rubicon in developing differentiated generics and specialty products for the US market with proprietary platforms.
- Zydus Lifesciences: Indian pharmaceutical company with strong US generics business and proprietary drug delivery technology platforms. Closely comparable to Rubicon's specialty generics + proprietary technology positioning across formulations.
- Glenmark Pharmaceuticals: Indian-headquartered pharmaceutical company with presence in generics, specialty, and branded markets globally. Comparable in regulated market focus and complex formulation capabilities.
- Endo International: US specialty pharmaceutical company with focus on difficult-to-manufacture generics and specialty therapeutics including CNS. Comparable to Rubicon's Validus-acquired CNS specialty positioning and emphasis on products without generic substitutes.
Direct peers
- Ajanta Pharma: Indian specialty generic pharmaceutical company focused on branded generics in emerging markets and US ANDA filings. Comparable to Rubicon in scale, business model, and focus on specialty/differentiated generics targeting regulated markets.
- Alembic Pharmaceuticals: Indian generic pharma company with US-focused API and finished dosage business. Closely comparable to Rubicon in product mix, US FDA approvals strategy, and export-led revenue model.
- Strides Pharma Science: Indian pharmaceutical company specializing in generic finished dosage formulations for regulated markets, particularly the US. Comparable to Rubicon in regulated market focus and complex generic portfolio, though Rubicon has stronger proprietary delivery technology.
- Granules India: Indian pharmaceutical manufacturer focused on generic finished dosages and API, with significant US presence. Comparable to Rubicon in vertically integrated manufacturing and US ANDA-based revenue model.
- Lannett Company: US-focused specialty generic pharmaceutical manufacturer. Comparable to Rubicon in US-market specialty generics positioning, though smaller and US-domestically headquartered rather than Indian-headquartered.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Rubicon Research social profiles
Digital presenceRubicon Research compliance and trust
Trust signalCompliance7 records
Rubicon Research financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rubicon Research leadership team
Management profileNumber of profiles
Profiles5 records
Rubicon Research subsidiaries and ownership
Company hierarchySubsidiaries8 records
Rubicon Research funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rubicon Research M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rubicon Research
What does Rubicon Research do?
Rubicon Research is a pharmaceutical formulations company that develops, manufactures, and commercializes generic and specialty pharmaceutical products, including drug-device combinations, primarily targeting the United States and other regulated markets. The company operates four manufacturing facilities (three in India and one R&D facility in Canada) and maintains a portfolio of 69 active ANDA/NDA products with 55 commercialized products in the US market.
Is Rubicon Research a public or private company?
Rubicon Research is a public company. It is classified as public and is currently operating.
When was Rubicon Research founded?
Rubicon Research was founded in 1999. It employs 251 to 500 people.
Where is Rubicon Research based?
Rubicon Research is headquartered in Mumbai, India, in the Asia region.
How does Rubicon Research make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are contract Manufacturing Services.
Who are Rubicon Research's main competitors?
Broad incumbents on record are Aurobindo Pharma, Lupin Limited, Zydus Lifesciences, Glenmark Pharmaceuticals and Endo International. Direct peers are Ajanta Pharma, Alembic Pharmaceuticals, Strides Pharma Science, Granules India and Lannett Company.
Does Rubicon Research have an API?
No public API is recorded for Rubicon Research.
What industry is Rubicon Research in?
Rubicon Research's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions, with a secondary code of HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA). Its NAICS code is 3254 and its SIC code is 2834.